Entopsis

Entopsis is a legitimate biotechnology entity (founded 2011) with a promising diagnostic platform (OpsisDX), backed by investors like Breakout Labs. However, the submission itself is of extremely low quality, containing factually incorrect claims (e.g., 'most people have used my product', 'audience reach: everyone') and inconsistent data (Name: 'ThunderHeart'). While the underlying technology is innovative and potentially useful, the lack of verifiable metrics and the presence of false traction claims in the submission severely penalize the PoU score, placing it in the 'minimal traction/unverified' tier.